-
EXCLUSIVE: AVEO CEO Explains How New Partnership Will Address $500 Million Opportunity Overseas
Monday, December 21, 2015 - 2:39pm | 828Read More...• AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has announced a partnership with EUSA Pharma granting EUSA exclusive European rights to tivozanib. • The deal could reportedly generate nearly $400 million for AVEO. • AVEO CEO Michael Bailey told Benzinga that the tivozanib deal is...
-
Illumina and Other Bargain Biotech Stocks Worth a Look Now
Wednesday, May 1, 2013 - 12:57pm | 916Read More...The research team at PropThink, which focuses on emerging growth companies in the health care sector, recently offered a list of bargain biotech stocks worth a look. The stocks that made the list include Endo Health Solutions (NASDAQ: ENDP), Illumina (NASDAQ: ILMN) and Keryx Biopharmaceuticals (...
-
JP Morgan Raises PT On AVEO Pharmaceuticals To $25
Tuesday, May 24, 2011 - 5:53am | 27Read More...JP Morgan has raised the price target on AVEO Pharmaceuticals (NASDAQ: AVEO) from $22 to $25 and maintains its Overweight rating.
-
J.P. Morgan Reports Partnership With Tivozanib A Big Win
Tuesday, February 22, 2011 - 12:07pm | 145Read More...J.P. Morgan has published a report on AVEO Pharmaceuticals (NASDAQ: AVEO). According to the report, the partnership with Tivozanib is a big win. “With this partnership, we now believe there is adequate funding to develop tivozanib in additional indications, which was a concern previously. Aveo will...
